Company intelligence / Profile preview

Aonix

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Aonix was a clinical-stage biopharmaceutical company primarily focused on the development of novel small molecule therapies for neurodegenerative disorders, with a specific emphasis on Alzheimer's disease. The company's lead research efforts centered on modulating key pathological proteins such as tau and amyloid-beta to slow or halt disease progression. Despite early-stage clinical interest, the company's operations were eventually ceased or integrated into other entities. Aonix is often noted in historical biotech records for its contributions to the early landscape of tau-targeting research.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Aonix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aonix.

Explore the full profile